Variant Synonymizer: Platform to identify mutations defined in different ways is available now!
Over 2,000 gene–disease validation summaries are now available—no login required!
Normosmic congenital hypogonadotropic hypogonadism (nCHH) is characterized by absent puberty with normal olfaction and has been attributed to autosomal recessive loss-of-function variants in TAC3. Five probands in three unrelated kindreds have biallelic TAC3 variants, supporting a strong gene–disease relationship (PMID:20194706, PMID:20332248).
Inheritance is autosomal recessive, with the recurrent intronic variant c.209-1G>C homozygous in three unrelated patients and segregating with disease in kindreds (PMID:20194706).
Case series identify multiple variant classes in TAC3: two splice-site mutations (c.209-1G>C, c.238+1G>C) abolish neurokinin B synthesis, and a missense variant c.187G>C (p.Ala63Pro) has been reported in an isolated nIHH patient (PMID:23329188).
Functional studies demonstrate that splicing mutations eliminate mature neurokinin B, resulting in low GnRH pulsatility and an elevated FSH/LH ratio that normalizes with pulsatile GnRH therapy, confirming a hypothalamic mechanism (PMID:20194706, PMID:20332248).
Population studies of common TAC3 variants show no significant association with age at menarche in the general population, arguing against a subtler modulatory effect (PMID:18728166).
Together, genetic and mechanistic data establish TAC3 biallelic loss-of-function as a strong cause of nCHH, warranting inclusion of TAC3 in diagnostic gene panels for congenital hypogonadotropic hypogonadism.
Gene–Disease AssociationStrongFive probands in three unrelated families; segregation and functional concordance Genetic EvidenceStrongMultiple biallelic splice-site and missense variants in five patients across independent kindreds Functional EvidenceModerateSplicing mutations abolish neurokinin B, GnRH pulsatility defects reversible with therapy; mechanistic expression data |